UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. (Q38412031)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 May 2015

Language	Label	Description	Also known as
English	UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.	scientific article published on 05 May 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

phase III clinical trial

0 references

Jean-Marie Boher

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

A Gonçalves

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-Y Pierga

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-M Ferrero

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M-A Mouret-Reynier

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

T Bachelot

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Delva

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Fabbro

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Lerebours

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-P Lotz

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Linassier

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Dohollou

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-C Eymard

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

B Leduc

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Lemonnier

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A-L Martin

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H Roché

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

5 May 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1692-1697

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Identifiers

10.1093/ANNONC/MDV216

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

release_pruagvpfyfhbhbegfhusxzw6py

1 reference

https://api.fatcat.wiki/v0/release/pruagvpfyfhbhbegfhusxzw6py

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38412031&oldid=1836548676"